Effects of oral orbifloxacin on fecal coliforms in healthy cats: a pilot study

The study objective was to determine the effect of oral orbifloxacin (ORB) onantimicrobial susceptibility and composition of fecal coliforms in cats. Nine cats wererandomized to two groups administered a daily oral dose of 2.5 and 5.0 mg ORB/kg for 7days and a control group (three cats per group). Coliforms were isolated from stoolsamples and were tested for susceptibilities to ORB and 5 other drugs. ORB concentrationin feces was measured using high-performance liquid chromatography (HPLC). The coliformswere undetectable after 2 days of ORB administration, and their number increased in mostcats after termination of the administration. Furthermore, only isolates ofEscherichia coli were detected in all cats before administration, andthose of Citrobacter freundii were detected after termination of theadministration. E. coli isolates exhibited high ORB susceptibility[Minimum inhibitory concentration (MIC), ≤0.125 µg/ml]or relatively low susceptibility (MIC, 1−2 µg/ml) with asingle gyrA mutation. C. freundii isolates largelyexhibited intermediate ORB susceptibility (MIC, 4µg/ml), in addition to resistance to ampicillin andcefazolin, and harbored qnrB, but not a gyrA mutation.HPLC revealed that the peaks of mean concentration were 61.3 and 141.0µg/g in groups receiving 2.5 and 5.0 mg/kg, respectively. Our findingssuggest that oral ORB may alter the total counts and composition of fecal coliform, but isunlikely to yield highly fluoroquinolone-resistant mutants of E. coli andC. freundii in cats, possibly because of the high drug concentration infeces.